Background. Annual influenza vaccine is recommended for those at greatest risk of severe influenza infection. Recent reports of a negative impact of serial influenza vaccination on vaccine effectiveness (VE) raises concerns about the recommendation for annual influenza vaccines, particularly in persons at greatest risk.
been observed with the Southern Hemisphere influenza vaccine or more severe cases requiring hospitalization remains uncertain.
Australia has sentinel surveillance systems for confirmed influenza based both in primary care as well as hospitals, and these allow estimates of VE to be made each year. Using subjects enrolled in the Australian influenza sentinel hospital surveillance program (2010) (2011) (2012) (2013) (2014) (2015) , we aimed to estimate VE against influenza-associated hospitalization in individuals who were vaccinated in ≥2 influenza seasons, compared to those vaccinated in the current season only and those previously vaccinated.
METHODS
The Influenza Complications Alert Network (FluCAN) was established in 2009 primarily to provide timely surveillance to public health authorities on hospitalizations with laboratory-confirmed influenza at multiple sentinel sites in Australia, with the number of sites increasing from 8 in 2009 to 17 in 2015 [11] . At participating sites, influenza testing is performed at the discretion of the treating clinician. Surveillance is conducted from April to November; annual influenza vaccination typically occurs between March and July with peak influenza activity usually occurring between July and September [12] [13] [14] [15] . Data sources included laboratory data and medical records supplemented by patient self-report. Comorbidities were defined as those listed as chronic medical conditions recommended to receive annual influenza vaccination including chronic organ dysfunction, immunosuppression, and diabetes and other chronic diseases [1] . Elderly patients were defined as those who were ≥65 years of age on admission.
An influenza case was defined as a patient (>9 years of age, where recommendations are universally for a single dose of vaccine per season) admitted to hospital with influenza confirmed by nucleic acid testing (NAT) using the polymerase chain reaction (PCR) performed at each hospital laboratory, all of which are nationally accredited. Test-negative controls were the next tested (within 2 weeks) hospitalized patient with acute respiratory illness (ARI) who had a negative influenza NAT. In 2011 and subsequently, up to 1 control was selected for each case so that the distribution of cases and controls over the study period was roughly balanced, but unmatched cases occurred in weeks where there were more cases than controls. In 2010, 2 controls were selected for each case. Patients were excluded if they did not have an ARI consistent with suspected influenza (particularly patients who underwent testing as part of routine bronchoscopy). We collected data on the date of onset of symptoms, the date of diagnostic test, and the date of admission.
Patients were defined as being currently vaccinated if they reported receiving a single dose of the current seasonal vaccine >2 weeks prior to presentation. Patients also reported whether they were vaccinated in the previous season. Data were collected prospectively from the medical record and/or patient interview, except for several hospitals that joined the system later after 2011; in those hospitals, data were collected retrospectively and thus vaccination status was determined solely from the medical record. These hospitals included 7 general hospitals that collected data retrospectively in the 2011 season, and 2 specialist pediatric hospitals that collected data retrospectively for the 2011-2013 seasons. In Australia, only nonadjuvanted, standard-dose, inactivated influenza vaccines were available during and prior to 2015. No live attenuated vaccines are available in Australia. All vaccines funded under the National Immunisation Program during the study period were trivalent inactivated influenza vaccines formulated according to World Health Organization recommendations; quadrivalent vaccine was only used in a limited number of persons in the final study year (2015).
We used an incidence density test-negative design to estimate VE, where controls were selected from hospitalizations without influenza contemporaneous to a case and thus frequency matched [16] [17] [18] . To reduce the impact of confounding, we constructed a propensity score from a number of demographic and clinical factors that were thought to influence a decision to vaccinate. These were age; sex; pregnancy; Indigenous ethnicity; the presence of any comorbidities (and interactions with age group); the number of chronic comorbidities; chronic cardiac, respiratory, renal, hepatic or neurological disease; diabetes; homelessness; residence in long-term-care facility; and current smoking. The propensity score was calculated from a logistic regression in control (influenza negative) patients and tested for calibration and discrimination from the area under the receiver operating characteristic curve and the Hosmer-Lemeshow test, respectively. Covariate balance was checked by inverse weighing on propensity score.
Vaccine effectiveness was estimated as VE = -( )1 0 0 q 1 % where q is the adjusted odds ratio of vaccination in case patients compared to test-negative control patients, estimated from conditional logistic regression using methods previously described [14, 19] . The adjusted odds ratio of vaccination in cases and controls was calculated stratified by year, site of enrollment, and quintile of propensity score. In the model, VE was estimated by comparing 3 groups against the reference group of those not vaccinated in either the season of enrollment (current) or the previous season (prior): (11) subjects vaccinated in both the current and previous seasons;64 (11) subjects vaccinated in the current season only;64(11) subjects vaccinated in the previous season only. VE was estimated in different subpopulations of interest (by age group, by the presence/absence of comorbid conditions), by year of enrollment, and by influenza subtype. Analyses were conducted on the complete set (excluding cases and controls where vaccinations status was missing); a sensitivity analysis was performed imputing missing data as described below.
A number of sensitivity analyses were performed. The first included only patients with a duration of illness ≤7 days at the time of testing to exclude the possibility that influenza was cleared over time. A second excluded patients with community-acquired pneumonia, as it was plausible that patients required treatment for secondary bacterial pneumonia rather than primary influenza infection. The third used multiple imputation of missing current and previous season vaccine status, using age group, comorbidities, pregnancy, Indigenous status, and influenza status using chained logistic models in 50 augmented datasets [20] . Analyses were performed using Stata 14.2 software for Windows (StataCorp, College Station, Texas)
RESULTS
Over the 6 seasons, there were 6223 patients aged >9 years admitted to a sentinel hospital with confirmed influenza. These were matched to 6505 patients with influenza-negative ARI. Of the patients with influenza, 4664 had influenza A detected (including 912 with A/H1N1, 779 with A/H3N2, and 2973 with unknown influenza A subtype) and 1559 had influenza B detected. Vaccination status in both years was ascertained in 61% of cases and 63% of controls; thus, the complete set analysis was performed using data from 3821 cases and 4115 controls ( Table 1) . Details of the propensity score calculation are provided in Table 2 . In control patients, the elderly, female patients, and patients with medical comorbidities were more likely to be vaccinated. Patients who were vaccinated in both years had a higher propensity score; those not vaccinated in either year, vaccinated in the current season only, or vaccinated in the 1 year prior had a lower propensity score (Figure 1 ). Those vaccinated only once in the 2 seasons were younger than those vaccinated in both years, with a lower proportion with medical comorbidities than those vaccinated (Table 3) .
Overall VE (2010) (2011) (2012) (2013) (2014) (2015) , stratified by quintile of propensity score, site, and year, was estimated to be 43% (95% confidence interval [CI], 37%-49%). Estimated vaccine effectiveness was higher in those vaccinated in both years than those vaccinated in the current year only or the previous year only (Figure 2) . VE was estimated to be 51% (95% CI, 45%-57%) in those vaccinated in both the current and previous years, compared with 33% (95% CI, 17%-47%) vaccinated in the current season only and 35% (95% CI, 21%-46%) in the previous season only. These differences were statistically significant (both seasons vs current season, P = .003; both seasons vs previous season, P = .002). A similar trend was observed in the elderly, in nonelderly adults, and in those with comorbidities ( Figure 2) .
When analyzed by year, the point estimate of VE was higher in those vaccinated in both years to those vaccinated in the current year except for 2012 (Figure 3) . Moreover, previous vaccination appeared to have a protective effect in the subsequent year, compared with no previous vaccine receipt. A similar pattern was observed against A/H1, A/H3, and influenza B strains. In a sensitivity analysis, imputation of missing vaccination status and exclusion of patients with community-acquired pneumonia or those with prolonged (>7 days) symptoms prior to presentation did not change the VE estimates significantly (Figure 4 ).
DISCUSSION
In this study, we found that Southern Hemisphere influenza vaccine in Australia in both the current and previous seasons was associated with a higher VE than vaccination in either single season. Vaccination with both current and previous-season influenza vaccine was highly correlated from season to season and resulted in significant protection against hospitalization from laboratory-confirmed influenza (ie, lower CI >0) in all Southern Hemisphere influenza seasons from 2011 to 2015 overall as well as for all influenza types.
Our results are in contrast to previously published studies from the Northern Hemisphere where repeated vaccination has resulted in reduced and sometimes minimal VE when compared with receipt of the current year's vaccination without prior vaccine receipt [5] [6] [7] 9] . Using patients from the [5, 6] . It should be noted that all these studies are based in primary care surveillance systems (assessing VE against medically presented influenza, rather than hospitalization) and vary in the magnitude of effect and statistical significance, even in adjacent countries in the same season [21, 22] .
Previous attempts to assess the impact of serial vaccination in the Southern hemisphere have been limited by cohort size [8] . These results presented provide reassurance that potential negative impacts of serial vaccination in the Southern Hemisphere are either not being observed or are limited and do not affect overall VE estimates, as we have shown for influenza-associated hospitalization.
Several explanations for the reduction in VE observed in the Northern Hemisphere have been proposed. A number of reports have demonstrated an impact of past vaccination on postvaccine serologic responses [23] [24] [25] [26] [27] . Earlier modeling simulations predict negative interference from previous vaccination when the antigenic distance between vaccine and circulating strains is large but between consecutive vaccine components is small [28] . It is therefore possible that interference is a significant phenomenon that will continue to occur with inactivated vaccines in specific influenza seasons and with specific types in the future. It is also possible that studies demonstrating an impact of serial vaccination have been influenced by bias with an inability to adjust for underlying differences between repeatedly vaccinated and infrequently vaccinated participants. The use of propensity scoring allows for statistical adjustment for many potential confounders. Indeed, in this study, we found systematic differences between those not vaccinated in either season, to those vaccinated in 1 season, to those vaccinated in both seasons.
A further explanation is that the apparent attenuation in vaccine protection is confounded by natural infection, as unvaccinated individuals are at higher risk of infection, which in itself elicits immunity [29] . This effect is likely to be small within a single season, but potentially significant over several seasons. The effect would be expected to be magnified if natural immunity has a stronger protective effect than vaccine-induced immunity. The ability to explore this is challenging given that the proportion of key population groups who acquire natural infection is not easily estimated outside of pandemic years.
The strengths to this study include enrolling children and adults from all states and territories in Australia. The significant cohort size, over multiple seasons and recruitment of hospitalized subjects, provides reassurance that any undetected negative impacts of serial vaccination are not being observed in the cohort most at risk of complications and mortality [23, 24, 28] . There are several limitations to this study. A significant proportion of patients did not have their vaccination status ascertained as, to date, the Australian Immunisation Register (previously the Australian Immunisation Childhood Register) has not recorded vaccination status of adults or children aged >7 years. Although the characteristics of patients for whom vaccination status was ascertained were similar to those in whom vaccination status was not obtained, we cannot exclude a systematic bias potentially influencing results. Vaccination status from the previous year may be subject to recall bias, and we did not verify vaccination records with primary care providers or other sources. Vaccine effectiveness estimates against subtypes must be interpreted with caution; subtyping information was not available in all patients. We note that apparent VE against each subtype was higher than the overall estimate, suggesting a potential bias. Finally, the results of this hospital-based study may not be directly comparable to other studies mainly based in primary care, although these have previously been found to be comparable [30] .
In summary, patients who receive serial influenza vaccination differ in several key respects to those who are serially unvaccinated, thereby highlighting the risk of exploring the impact of previous vaccination history on current-season VE estimates. Using propensity scores to adjust for potential confounders, we did not find any evidence that serial vaccination was associated with an attenuation in influenza vaccine protection against hospitalization compared to those unvaccinated. Further work is required to determine the relative contributions of immunological interference, confounding by indication and other factors, and confounding by natural infection on estimates of VE over longer periods. These data reinforce recommendations for annual influenza vaccination, particularly among individuals at greatest risk of influenza disease.
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